CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$14.62
-0.57 (-3.75%)
▼
5d:
-5.86%
30d:
+29.38%
90d:
+13.6%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTNM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CTNM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $14.62, which is considered slightly high relative to its 30-day fair value range of $11.73 to $15.02.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $13.51, while resistance sits at $16.91. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CTNM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.33 (+52.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $13.51, while resistance sits at $16.91. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CTNM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.33 (+52.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$11.73 -
$15.02
Company Quality Score
60/100
(BUY)
Options IV Signal
21th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 21th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 52.8% below Wall St target ($22.33)
- CAUTION: Recommendation downgraded due to -5.9% 5-day decline
Trading Range Analysis
30-Day Trading Range
$11.73 -
$15.02
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.73
(25.5%)
Support & Resistance Levels
Support Level
$13.51
Resistance Level
$16.91
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.06
Wall Street Target
$22.33
(+52.8%)
Share & Embed Analysis
Last updated: July 13, 2026 6:01 PM ET
Data refreshes hourly during market hours. Next update: 7:01 PM
Data refreshes hourly during market hours. Next update: 7:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 45 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 51 HOLD |
